Reposted from HDBuzz.net
UniQure has announced positive top-line results from its Phase I/II trial of AMT-130, a one-time gene therapy being tested in people with Huntington’s disease (HD). Topline data is a summary of the key results from a study that is released quickly after data becomes available to the company at a specified timepoint. In this update, uniQure reports that symptom progression is being significantly slowed by the drug, and the primary endpoint of the trial was met. This is the first time any drug has been shown to alter the course of HD in people in a clinical trial. HDBuzz caught up with uniQure’s Chief Medical Officer Walid Abi-Saab and CEO Matt Kapusta to get clarity for the HD community around this update. Let’s get into the details of this drug and the update uniQure have shared.
More News
Image
Graduate researchers showcase innovation and entrepreneurship at GRIP 2026
The annual student-led symposium brought together attendees to showcase graduate research, hear from industry and alumni speakers, and explore the role of innovation and future technologies in advancing health care.
Read More
Image
Convocation speaker Dimitris Polygenis encourages graduates to embrace unexpected opportunities
McKesson Canada president and U of T pharmacy alum shared how pharmacists can apply learnings and values across the profession.
Read More
Image
“Support doesn’t always come in the form of a prescription”
Shasha Wolfe shares lived experiences accessing gender-affirming care with PharmD students to highlight importance of pharmacists in providing support.
Read More